AVEO initiate Phase Ib trial with VEGFR inhibitor AV-951

AVEO Pharmaceuticals has initiated a Phase Ib clinical study its  VEGFR 1/2/3 receptor inhibitor AV-951.

Piramed/Genentech publish data on PI3K inhibitor GDC-0941

Piramed/Genentech have published research leading to the development of lead compound GDC-0941

Novartis publish series of benzimidazole lck inhibitors

Novartis have published a series of benzimidazole lck inhibitors

Sunesis publish series of Polo Like Kinase inhibitors

Sunesis have published two series of Polo-like kinase (PLK) inhibitors:

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

Abbott publish series of PIM-1/2 kinase inhibitors

Abbott have published a series of Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-dione Pim-1/Pim-2 kinase inhibitors

Gleevec receives priority review in US for GIST after surgery

Gleevec (imatinib) has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

UKs NICE recommends Lucentis for Wet AMD

The UK’s NICE final guidance has recommended Lucentis as a cost-effective treatment for wet AMD